jublia Drug Patent Profile
✉ Email this page to a colleague
When do Jublia patents expire, and when can generic versions of Jublia launch?
Jublia is a drug marketed by Bausch and is included in one NDA. There are eighteen patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-five patent family members in twenty-four countries.
The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jublia
A generic version of jublia was approved as efinaconazole by TEVA PHARMS USA on December 16th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for jublia?
- What are the global sales for jublia?
- What is Average Wholesale Price for jublia?
Summary for jublia
International Patents: | 85 |
US Patents: | 18 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 64 |
Clinical Trials: | 4 |
Patent Applications: | 271 |
Drug Prices: | Drug price information for jublia |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for jublia |
What excipients (inactive ingredients) are in jublia? | jublia excipients list |
DailyMed Link: | jublia at DailyMed |
Recent Clinical Trials for jublia
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Dong-A ST Co., Ltd. | Phase 4 |
University of Alabama at Birmingham | Phase 4 |
University of Alabama at Birmingham | N/A |
Pharmacology for jublia
Drug Class | Azole Antifungal |
Paragraph IV (Patent) Challenges for JUBLIA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
JUBLIA | Topical Solution | efinaconazole | 10% | 203567 | 19 | 2018-06-06 |
US Patents and Regulatory Information for jublia
jublia is protected by eighteen US patents.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567-001 | Jun 6, 2014 | AB | RX | Yes | Yes | 7,214,506 | ⤷ Subscribe | ⤷ Subscribe | |||
Bausch | JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567-001 | Jun 6, 2014 | AB | RX | Yes | Yes | 9,302,009 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
Bausch | JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567-001 | Jun 6, 2014 | AB | RX | Yes | Yes | 11,654,139 | ⤷ Subscribe | ⤷ Subscribe | |||
Bausch | JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567-001 | Jun 6, 2014 | AB | RX | Yes | Yes | 10,512,640 | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for jublia
See the table below for patents covering jublia around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2112228 | ⤷ Subscribe | |
Japan | 2020169207 | 安定化エフィナコナゾール組成物 (STABILIZED EFINACONAZOLE COMPOSITIONS) | ⤷ Subscribe |
Japan | 2017500374 | 抗感染方法、抗感染組成物、および抗感染装置 | ⤷ Subscribe |
Spain | 2532133 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Jublia Market Analysis and Financial Projection Experimental
More… ↓